Aegerion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AEGR)

$1.97 0.10 (5.35 %)
(As of 11/17/2017 05:25 AM ET)
Previous Close$1.87
Today's Range$1.86 - $2.34
52-Week Range$1.23 - $10.85
Volume2.17 million shs
Average Volume635,262 shs
Market Capitalization$56.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5

About Aegerion Pharmaceuticals (NASDAQ:AEGR)

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Sector: Pharmaceuticals - NEC
  • Symbol: NASDAQ:AEGR
  • CUSIP: 00767E10
  • Web: www.aegerion.com
Debt:
  • Debt-to-Equity Ratio: -19.22%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.67%
Profitability:
  • Trailing EPS: ($5.97)
  • Net Margins: -75.07%
  • Return on Assets: -29.21%
Misc:
  • Employees: 318
  • Outstanding Shares: 29,540,000
 

Frequently Asked Questions for Aegerion Pharmaceuticals (NASDAQ:AEGR)

What is Aegerion Pharmaceuticals' stock symbol?

Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."

How were Aegerion Pharmaceuticals' earnings last quarter?

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) issued its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company earned $35.70 million during the quarter, compared to analyst estimates of $43 million. Aegerion Pharmaceuticals's revenue was down 39.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.

Where is Aegerion Pharmaceuticals' stock going? Where will Aegerion Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued 1 year price targets for Aegerion Pharmaceuticals' shares. Their forecasts range from $1.50 to $1.50. On average, they anticipate Aegerion Pharmaceuticals' stock price to reach $1.50 in the next twelve months. View Analyst Ratings for Aegerion Pharmaceuticals.

Who are some of Aegerion Pharmaceuticals' key competitors?

How do I buy Aegerion Pharmaceuticals stock?

Shares of Aegerion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aegerion Pharmaceuticals' stock price today?

One share of Aegerion Pharmaceuticals stock can currently be purchased for approximately $1.97.

How big of a company is Aegerion Pharmaceuticals?

Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe.

How can I contact Aegerion Pharmaceuticals?

Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.


MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aegerion Pharmaceuticals (NASDAQ:AEGR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.50 (23.86% downside)

Consensus Price Target History for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Price Target History for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/30/2016Cowen and CompanyReiterated RatingHold$1.50N/AView Rating Details
11/11/2016J P Morgan Chase & CoInitiated CoverageHoldN/AView Rating Details
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00N/AView Rating Details
2/12/2016Bank of America CorporationDowngradeNeutral -> Underperform$6.00N/AView Rating Details
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Earnings by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Earnings History by Quarter for Aegerion Pharmaceuticals (NASDAQ AEGR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details
8/5/2015Q2($0.27)($0.01)$58.98 million$64.20 millionViewN/AView Earnings Details
10/30/2014Q314($0.18)($0.12)$48.60 million$43.70 millionViewN/AView Earnings Details
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details
5/6/2014Q1($0.35)($0.54)$33.58 million$27.00 millionViewListenView Earnings Details
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aegerion Pharmaceuticals (NASDAQ AEGR)

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ AEGR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy75,000$1.75$131,250.00View SEC Filing  
9/12/2016Healthcare Master Fun BroadfinMajor ShareholderBuy276,000$1.66$458,160.00View SEC Filing  
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Latest Headlines for Aegerion Pharmaceuticals (NASDAQ AEGR)

Source:
DateHeadline
Head-To-Head Comparison: Aegerion Pharmaceuticals (AEGR) and Neos Therapeutics (NEOS)Head-To-Head Comparison: Aegerion Pharmaceuticals (AEGR) and Neos Therapeutics (NEOS)
www.americanbankingnews.com - November 8 at 7:28 PM
Aegerion Pharmaceuticals (AEGR) & Its Rivals Head-To-Head AnalysisAegerion Pharmaceuticals (AEGR) & Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - October 20 at 12:22 PM
Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
finance.yahoo.com - October 5 at 12:21 PM
Aegerions Juxtapid Gets Pricing Authorization in JapanAegerion's Juxtapid Gets Pricing Authorization in Japan
finance.yahoo.com - October 5 at 12:21 PM
Criminal and civil actions filed against Aegerion Pharmaceuticals Inc.Criminal and civil actions filed against Aegerion Pharmaceuticals Inc.
www.prnewswire.com - September 23 at 9:33 AM
Head to Head Review: Novo Nordisk A/S (NVO) vs. Aegerion Pharmaceuticals (NASDAQ:AEGR)Head to Head Review: Novo Nordisk A/S (NVO) vs. Aegerion Pharmaceuticals (NASDAQ:AEGR)
www.americanbankingnews.com - August 15 at 6:32 AM
Tetraphase Pharmaceuticals (TTPH) and Aegerion Pharmaceuticals (NASDAQ:AEGR) Head-To-Head AnalysisTetraphase Pharmaceuticals (TTPH) and Aegerion Pharmaceuticals (NASDAQ:AEGR) Head-To-Head Analysis
www.americanbankingnews.com - July 30 at 12:20 AM
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a MaterAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater
biz.yahoo.com - November 30 at 10:12 AM
Aegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID PricingAegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID Pricing
www.streetinsider.com - November 19 at 8:26 PM
Aegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID Pricing - StreetInsider.comAegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID Pricing - StreetInsider.com
www.streetinsider.com - November 17 at 8:35 PM
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - November 7 at 9:49 PM
Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3
www.zacks.com - November 4 at 3:16 PM
Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3 - NasdaqAegerion (AEGR) Reports Narrower-than-Expected Loss in Q3 - Nasdaq
www.nasdaq.com - November 4 at 12:52 PM
Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial ... - GlobeNewswire (press release)Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial ... - GlobeNewswire (press release)
globenewswire.com - November 4 at 12:52 PM

Social Media

Financials

Chart

Aegerion Pharmaceuticals (NASDAQ AEGR) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.